Quinagolide

Chemical compound From Wikipedia, the free encyclopedia

Quinagolide (INNTooltip International nonproprietary name, BANTooltip British Approved Name), sold under the brand name Norprolac, is a selective dopamine D2 receptor agonist which is used to manage hyperprolactinemia.[1] It has also been found to be effective in the treatment of breast pain.[2] It is used in the UK, but it is not available in US.

Quick facts Clinical data, Trade names ...
Quinagolide
Clinical data
Trade namesNorprolac
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
Drug classDopamine receptor agonist
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N,N-diethyl-N-[(3S,4aS,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-3-yl]sulfamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC20H33N3O3S
Molar mass395.56 g·mol−1
  • InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1 checkY
  • Key:GDFGTRDCCWFXTG-ZIFCJYIRSA-N checkY
Close

Chemistry

Quinagolide is a racemate composed of the following two enantiomers:[3]

More information Enantiomeres of Quinagolide ...
Enantiomeres of Quinagolide

(+)-Quinagolid
CAS number: 140630-79-1

(-)-Quinagolid
CAS number: 140630-80-4
Close

Synthesis

The first synthesis of quinagolide was disclosed in patents filed by Sandoz.[4]

A sequence of nine steps is required to transform the starting material 5-methoxy-2-tetralone (1) into the octahydrobenzo[g]quinoline ring system with the correct stereochemistry required. This intermediate (11) is then converted in another five steps to the drug. Transformation of the ester (13) into the amine (15) is accomplished by a Curtius rearrangement in which an acyl hydrazide is treated with nitrosyl chloride.[4][5][6]

Manufacture

The laboratory route was not practical for the synthesis of quinagoline on a large scale. Therefore scientists at Novartis developed an improved process.[7]

The starting material is 1,6-dimethoxynaphthalene (1). This is selectively lithiated at the C-7 position and reacts with (2Z)-ethyl 2-cyano-3-ethoxyacrylate (2), to give the cyanoacrylate (3). Catalytic hydrogenation and hydrolysis produces (5). Birch reduction of (5) leads first to (6) which on acid work-up gives the imine (7), which is reduced with sodium borohydride to yield (8). Fischer esterification with methanol gives an ester that is next alkylated with 1-iodopropane to give (11). The required stereochemistry for quinagoline is set in the final steps.[7][8][9]

See also

References

Related Articles

Wikiwand AI